Related Experiment Videos
Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma
1Department of Pathology, University of Arizona Health Sciences Center, Tucson 85724.
Journal of Cellular Biochemistry. Supplement
|January 1, 1994
Summary
Prostate cancer cells alter their extracellular matrix and integrin expression. Key proteins like matrilysin are active in carcinomas, indicating potential therapeutic targets.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Prostate carcinoma basal lamina composition differs from normal glands.
- Integrin expression and localization change in prostate cancer cells.
- Extracellular matrix remodeling proteins are altered in prostate cancer.
Purpose of the Study:
- To investigate changes in basal lamina, integrin expression, and metalloproteinase activity in prostate carcinoma.
- To compare the molecular characteristics of normal prostate glands with cancerous tissues.
- To identify potential biomarkers for prostate cancer progression.
Main Methods:
- Immunohistochemistry to analyze protein expression and localization.
- Transmission electron microscopy (TEM) for ultrastructural analysis.
- Northern analysis, Western blotting, and zymogram analysis for metalloproteinase activity.
Main Results:
- Prostate carcinomas show altered basal lamina composition with variations in laminin and tenascin.
- Integrin expression (e.g., alpha 6 beta 4) is disrupted, with diffuse cytoplasmic membrane localization in cancer cells.
- Three matrix metalloproteinases (matrilysin, gelatinase A, gelatinase B) are identified, with active matrilysin being prominent in carcinomas and precursor lesions.
Conclusions:
- Prostate carcinoma is characterized by significant alterations in the extracellular matrix and cell adhesion molecules.
- The presence of active matrilysin in prostate cancer and prostatic intraepithelial neoplasia suggests its role in tumor progression.
- These molecular changes offer potential targets for diagnostic and therapeutic strategies in prostate cancer.